ABMD News and Press, ABIOMED Inc. From 01/28/21

Abiomed (ABMD): FQ3 Non-GAAP EPS of $1.17 beats by $0.07; GAAP EPS of $1.35 beats by $0.23.Revenue of $231.7M (+4.6% Y/Y) beats by $5.39M.Press Release For further details see: Abiomed EPS beats by $0.07, beats on revenue

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported record revenue in the third quarter fiscal 2021 of $231.7 million, a year over year increase of 5% compared to Q3 fiscal year 2020 despite the negative impact of COVID-19. Operatin...

Abiomed (NASDAQ:ABMD) is scheduled to announce FQ3 earnings results on Thursday, January 28th, before market open.The consensus EPS Estimate is $1.10 (-1.8% Y/Y) and the consensus Revenue Estimate is $226.31M (+2.1% Y/Y).Analysts estimate gross margin of 81.2%.Over the last 2 years, ABMD has ...

The following slide deck was published by Abiomed, Inc. in conjunction with this event. For further details see: Abiomed (ABMD) Presents At 39th Annual Healthcare Conference - Slideshow

Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, January 28, 2021, the Company will release financial results for the third quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, January 28, 2021 at 8:00 a.m. ET. Michael R. Minog...

Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed’s robust intellectual property portfolio protects its current and future pump and catheter designs, along with other product components ...

Abiomed's AAA financials, including a clean balance sheet and world-class margins can justify a premium in its valuation. Discounting Abiomed's future free cash flows, we derive the stock's intrinsic value, which comes to around ~$340/share, which is quite close to Abiomed's current s...

Tesla topped both the S&P 500 and Nasdaq 100 benchmark indexes for 2020, while Apple aced the Dow Jones Industrials, according to MarketWatch.com.The S&P 500 (SPY) rose 16.3% in 2020, and these are the top 20 S&P stocks for the year: [[TSLA]] +743%, [[ETSY]] +302%, [[NVDA]] +122%,...

"Reversion to the mean" and "momentum" are polar opposite concepts in market lore, with acolytes in either congregation loudly pledging their allegiance. The truth is, as it were, always in the middle as the same stocks keeping making a list of the year's top winners and losers, be it in slot...

As the year closes out, Abiomed (ABMD) is leading the S&P 500 constituents to become the highest gainer for 2020. With the 2.6% added today, the total return for the year is reaching 83.4% YTD, well outperforming the 17.8% gain in the SPDR S&P 500 Trust ETF (SPY). ...